1001201-61-1

Basic information

• Product Name: tert-butyl 4-((5R,7S)-7-hydroxy-5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-((5R,7S)-7-hydroxy-5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate;tert-butyl (5R,7R)-6,7-dihydro-7-hydroxy-5-Methyl-5H-cyclopenta[d]pyriMidin-4-ylcarbaMate;4-[(5R,7S)-6,7-Dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester
• CAS NO: 1001201-61-1
• Molecular Formula: C₁₇H₂₆N₄O₃
• Molecular Weight: 334.41334
• Mol File: 1001201-61-1.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl 4-((5R,7S)-7-hydroxy-5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-((5R,7S)-7-hydroxy-5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate(1001201-61-1)
• EPA Substance Registry System: tert-butyl 4-((5R,7S)-7-hydroxy-5-Methyl-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate(1001201-61-1)

Safety Data

• Hazardous Substances Data: 1001201-61-1(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-((5R,7S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate is a chemical compound that is used in medicinal chemistry research as a potential drug candidate. It is a piperazine derivative with a cyclopenta[d]pyrimidine moiety, and its tert-butyl ester group provides stability and enhances its pharmacokinetic properties. The compound has shown potential for therapeutic applications in the treatment of various diseases, particularly in the modulation of biological pathways associated with the targeted receptor. Further research and development efforts are underway to explore its pharmacological properties and evaluate its potential for clinical use.

Upstream product

• 1001180-15-9 tert-butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-piperazine-1-carboxylate 
• 1001180-49-9 tert-butyl 4-((5R,7S)-5-methyl-7-((4-nitrobenzoyl)oxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-piperazine-1-carboxylate 
• 1001180-21-7 (R)-tert-butyl 4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperazine-1-carboxylate 
• 1097870-93-3 tert-butyl 4-((5R,7S)-7-(4-bromobenzoyloxy)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate 
• 89-82-7 pulegone 
• 623935-92-2 ethyl (2R)-2-methyl-5-(propan-2-ylidene)cyclopentanecarboxylate 
• 85440-74-0 (2R)-2-methyl-5-oxocyclopentanecarboxylic acid ethyl ester 
• 1001178-85-3 (R)-2-mercapto-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 1001180-40-0 (R)-4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-5-methyl-6,7-dihydro-5H-cyclopenta[d]-pyrimidine 1-oxide 
• 1001180-18-2 tert-butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-piperazine-1-carboxylate 
• 1001178-87-5 (R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 1001180-35-3 (R)-ethyl 2-amino-5-methylcyclopent-1-enecarboxylate 
• 953045-35-7 (R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine 
• 1001178-90-0 (R)-tert-butyl 4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperazine-1-carboxylate 

Downstream Products

• 1001180-49-9 tert-butyl 4-((5R,7S)-5-methyl-7-((4-nitrobenzoyl)oxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-piperazine-1-carboxylate 

Relevant articles and documents

Asymmetric Synthesis of Akt Kinase Inhibitor Ipatasertib

A highly efficient asymmetric synthesis of the Akt kinase inhibitor ipatasertib (1) is reported. The bicyclic pyrimidine 2 starting material was prepared via a nitrilase biocatalytic resolution, halogen-metal exchange/anionic cyclization, and a highly dia

Synthesis of Akt inhibitor ipatasertib. part 2. Total synthesis and first kilogram scale-up

Herein, the first-generation process to manufacture Akt inhibitor Ipatasertib through a late-stage convergent coupling of two challenging chiral components on multikilogram scale is described. The first of the two key components is a trans-substituted cyc

COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE

The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hy